This research examined 326 people with HIV who were already controlling their virus. They switched from an older drug combination to either a bictegravir-based or dolutegravir-based regimen. The goal was to see how weight, cholesterol, blood sugar, and uric acid levels changed over two years.
Between the two new drug groups, there were no significant differences in how these metabolic markers changed over time. Both groups saw some weight gain and increases in uric acid, but the overall patterns were similar. Smoking, high blood pressure, and older age were also linked to higher levels of certain fats and sugars in the blood.
While the study offers useful real-world data, it is limited by its small size and lack of a control group. Readers should understand that individual factors like lifestyle and existing health conditions play a huge role. Doctors should continue to choose medications based on each patient's specific needs while managing traditional risk factors.
